Achondroplasia Treatment Market Projected to Reach USD 3.2 Billion by 2034, Unveils Dynamics, Segmentation, and Growth Opportunities – By PMI
February 01, 2024 07:01 ET
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Achondroplasia Treatment Market size was valued at about USD 120.4 million in 2024 and expected to grow at CAGR...
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
March 03, 2022 07:30 ET
|
Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BridgeBio Pharma, Inc. Merger
December 02, 2020 14:39 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO) regarding possible breaches...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Eidos Therapeutics, Inc. Buyout
October 05, 2020 21:00 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ GS: EIDX) regarding possible breaches of...